| 基线Anti-HBc联合HBsAg预测聚乙二醇干扰素α-2a在恩替卡韦经治慢性乙型肝炎的治疗应答 |
| |
| 引用本文： | 廖金瑶,陈学福,陈小苹,肖艺.基线Anti-HBc联合HBsAg预测聚乙二醇干扰素α-2a在恩替卡韦经治慢性乙型肝炎的治疗应答[J].循证医学,2017,17(5):287-292. |
| |
| 作者姓名： | 廖金瑶 陈学福 陈小苹 肖艺 |
| |
| 作者单位： | 广东省人民医院感染科、广东省医学科学院, 广州 510080 |
| |
| 基金项目： | 广东省中医药局建设中医药强省科研课题资助项目（20141006） |
| |
| 摘 要： |
|
| 关 键 词： | 慢性乙型肝炎 基线Anti-HBc 聚乙二醇干扰素α -2a 恩替卡韦 |
Baseline Anti-HBc Combined with HBsAg Predicts Treatment Response of Peg-IFNα-2a in Chronic Hepatitis B Patients Receiving Entecavir |
| |
| LIAO Jin-yao,CHEN Xue-fu,CHEN Xiao-ping,XIAO Yi.Baseline Anti-HBc Combined with HBsAg Predicts Treatment Response of Peg-IFNα-2a in Chronic Hepatitis B Patients Receiving Entecavir[J].The Journal of Evidence-Based Medicine,2017,17(5):287-292. |
| |
| Authors: | LIAO Jin-yao CHEN Xue-fu CHEN Xiao-ping XIAO Yi |
| |
| Institution: | Department of Infectious Diseases, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China |
| |
| Abstract: | |
| |
| Keywords: | chronic hepatitis B baseline Anti-HBc Peginterferon Interferons α -2a Entecavir |
|
| 点击此处可从《循证医学》浏览原始摘要信息 |
| 点击此处可从《循证医学》下载免费的PDF全文 |
